title: Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes.
abstract: The effect of dapagliflozin on blood pressure was evaluated in non-hypertensive (<140 mm Hg) and hypertensive (⩾140 mm Hg) patients with type 2 diabetes mellitus. Data were pooled from 13 placebo-controlled studies. Patients received dapagliflozin 10 mg/day (n = 2360) or placebo (n = 2295) for up to 24 weeks. Dapagliflozin was associated with placebo-subtracted changes from baseline in systolic and diastolic blood pressures of -3.6 and -1.2 mm Hg, respectively, in hypertensive patients and -2.6 and -1.2 mm Hg, respectively, in non-hypertensive patients. At 24 weeks, a similar proportion of patients experienced measured orthostatic reactions with dapagliflozin versus placebo in hypertensive (6.1% and 6.6%, respectively) and non-hypertensive (4.0% and 4.2%) patients. No clinically relevant difference was observed between dapagliflozin and placebo in heart rate. In conclusion, dapagliflozin 10 mg induces a modest reduction in blood pressure compared with placebo in patients with diabetes with a low risk of orthostatic reactions, regardless of baseline blood pressure.
authors.affiliation: AstraZeneca, Mölndal, Sweden david.sjostrom1@astrazeneca.com.
authors.forename: C David
authors.initials: CD
authors.lastname: Sjöström
authors.affiliation: AstraZeneca, Mölndal, Sweden.
authors.forename: Peter
authors.initials: P
authors.lastname: Johansson
authors.affiliation: Bristol-Myers Squibb, Princeton, NJ, USA.
authors.forename: Agata
authors.initials: A
authors.lastname: Ptaszynska
authors.affiliation: Bristol-Myers Squibb, Princeton, NJ, USA Formerly Bristol-Myers Squibb, Princeton, NJ, USA.
authors.forename: James
authors.initials: J
authors.lastname: List
authors.affiliation: AstraZeneca, Mölndal, Sweden.
authors.forename: Eva
authors.initials: E
authors.lastname: Johnsson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D001795:Blood Pressure Determination / Q000379:methods; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; C529054:dapagliflozin
keywords: Dapagliflozin; blood pressure; hypertension; sodium-glucose co-transporter 2 inhibitor; type 2 diabetes